| Entry |
|
|---|
| Name |
Bivalirudin trifluoroacetate (USAN);
Angiomax (TN) |
|---|
| Product |
|
|---|
| Generic |
BIVALIRUDIN (Accord Healthcare), BIVALIRUDIN (Athenex Pharmaceutical Division), BIVALIRUDIN (Avenacy), BIVALIRUDIN (Civica), BIVALIRUDIN (Dr. Reddy's Laboratories Limited), BIVALIRUDIN (Eugia US LLC), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Hainan Shuangcheng Pharmaceuticals), BIVALIRUDIN (Meitheal Pharmaceuticals), BIVALIRUDIN (Meitheal Pharmaceuticals), BIVALIRUDIN (Mylan Institutional LLC), BIVALIRUDIN (Pharma Packaging Solutions), BIVALIRUDIN (Sandoz), BIVALIRUDIN (Sandoz), BIVALIRUDIN (Slate Run Pharmaceuticals) |
|---|
| Formula |
C98H138N24O33. (C2HF3O2)2
|
|---|
| Exact mass |
2406.9715
|
|---|
| Mol weight |
2408.33
|
|---|
| Class |
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
|
|---|
| Remark |
| Product (DG02963): | D11280<US> |
|
|---|
| Efficacy |
Anticoagulant, Thrombin inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa04610 | Complement and coagulation cascades |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B01 ANTITHROMBOTIC AGENTS
B01A ANTITHROMBOTIC AGENTS
B01AE Direct thrombin inhibitors
B01AE06 Bivalirudin
D11280 Bivalirudin trifluoroacetate (USAN) <US>
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
DG02963 Bivalirudin
D11280 Bivalirudin trifluoroacetate
Target-based classification of drugs [BR:br08310]
Peptidases and inhibitors
Serine peptidases
Chymotrypsin family
F2a
D11280 Bivalirudin trifluoroacetate (USAN) <US>
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
DG02963 Bivalirudin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
